The human body has an Endocannabinoid System (ECS), not a Benzodiazepine System. The receptors of the ECS system (namely CB1) play pivotal roles in anxiolytic action of benzodiazepines. In other words, benzodiazepine drugs (such as Alprazolam -“Xanax”; Chlordiazepoxide -“Librium”; Clobazepam – “Onfi”; Clonazepam -“Klonopin”; and many others) have an anxiolytic mechanism of action that utilize the ECS receptor CB1.   The ECS is emerging as primary drug targets for treating numerous neurological disorders including: Parkinson’s disease; Alzheimer’s disease; multiple sclerosis; neuropathic pain; schizophrenia; anxiety; depression; addiction; post-concussion syndrome, and post-traumatic stress disorders. Many peer reviewed research papers are using phytocannabinoids such as CBD to confirm the widely held assertion that natural plant medicine is as effective as pharmaceutical drugs for addressing nurological discorders.